Indivior Pharmaceuticals Q3 2026 earnings
Record quarterly SUBLOCADE net revenue and adjusted EBITDA drove a 13% YoY revenue increase and a 76% YoY adjusted EBITDA rise.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $356M | +13% | — | Ex. 99.1, income statement |
| EPS (GAAP) | $1.12 | +239% | — | Ex. 99.1, income statement |
| EPS (adjusted) | $1.32 | +83% | — | Ex. 99.1, income statement |
| Net income | $137M | +226% | — | Ex. 99.1, income statement |
| Adj. EBITDA | $211M | +76% | — | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| US: SUBLOCADE* | $252M | +24% | 71% | Record quarterly total SUBLOCADE net revenue |
| US: Sublingual & other | $53M | +4% | 15% | — |
| US: OPVEE1 | $0 | -100% | 0% | Discontinuation of OPVEE sales and marketing |
| US: PERSERIS2 | $2M | -67% | 1% | — |
| US: Total U.S. | $307M | +15% | 86% | — |
| Rest of World | $48M | +2% | 13% | — |
| Total Net Revenue | $356M | +13% | 100% | — |
Margins and costs
- Gross margin 85.6% (prior 76.1%, change +9.5 pp)
- Operating expenses $125M (+33% YoY)
- One-offs in the quarter Loss on debt extinguishment $18M; Litigation settlement expense $1M; Discontinuation of OPVEE sales and marketing $30M
- Effective tax rate 25% (prior-year 12%, year-to-date 24%)
- Non-GAAP bridge Adds back stock-based compensation, corporate initiative transition, manufacturing transition, loss on debt extinguishment, and litigation settlement expense.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Adjusted EBITDA margin | 59% | 54% | 38% | +21 pp YoY |
| Net income margin | 39% | 36% | 13% | +26 pp YoY |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Full-year 2026 total SUBLOCADE net revenue growth | 20% year-over-year | 20% year-over-year | — |
| Full-year 2026 adjusted EBITDA growth | 68% year-over-year at the midpoint | 68% year-over-year at the midpoint | — |
What drove it
- Revenue story Total net revenue grew 13% YoY driven by a 24% YoY increase in US SUBLOCADE net revenue to $252M, partially offset by a 67% YoY decline in US PERSERIS revenue to $2M and the discontinuation of OPVEE sales.
- EPS story EPS growth was driven by higher net income margins and lower tax expenses, with net income rising 226% YoY to $137M.
- One-off check Loss on debt extinguishment $18M (non-recurring), Litigation settlement expense $1M (non-recurring), Discontinuation of OPVEE sales and marketing $30M (non-recurring)
The good
- Record quarterly total SUBLOCADE net revenue of $267M, up 22% YoY
- Record quarterly adjusted EBITDA of $211M, up 76% YoY
- Adjusted EBITDA margin of 59%, up 21 pp YoY
The bad
- US PERSERIS revenue declined 67% YoY to $2M
- Discontinuation of OPVEE sales and marketing reduced revenue by $30M YoY
The ugly
- none
Open questions
- How will the discontinuation of OPVEE sales and marketing impact future revenue mix?
- What is the expected impact of the pending merger with Supernus on the 2026 financial guidance?
Full release
Earnings: INDV — filed 2026-10-29
Indivior Reports Third Quarter 2026 Financial Results
• Q3’26 Total Net Revenue of $356 Million, Up 13% YoY
• Record Quarterly Total SUBLOCADE®
Net Revenue of $267 Million in
Q3’26, Up 22% YoY
• Record Quarterly Net Income of $137 Million and Record
Non-GAAP
Net Income of $161 Million in Q3’26
• Record Quarterly Adjusted
EBITDA of $211 Million in Q3’26, Up 76% YoY
• Net Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA
Margin of 59%, Up 2,100 Basis Points YoY
• On Track to Close Merger with Supernus on November 2nd
Richmond, VA, October 29, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2026.
“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda,” said Joe Ciaffoni, Chief Executive Officer. “Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda. I want to thank the Indivior team for their commitment and hard work that generated these results and made the transaction with Supernus possible. I am confident in Supernus’ future and its ability to build on this strong foundation for people living with central nervous system diseases and to create long-term value for shareholders.”
“We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2100 basis points year-over-year,” said Ryan Preblick, Chief Financial Officer. “Our strong results and the execution of our Indivior Action Agenda puts us on track to achieve our previously communicated 2026 financial guidance, excluding the impact of our pending acquisition. Strong cash generation brought cash and investments to $332 million at quarter end, adding to the financial strength we will bring to our merger with Supernus.”
Q3 2026 Business Highlights
:
Full-Year 2026 Financial Guidance
:
Prior to the closing of the merger, Indivior is on track to achieve its previously communicated full year 2026 guidance as a standalone organization. That guidance assumed no material change in exchange rates for key currencies compared with 2025 average rates, notably USD/GBP and USD/EUR. Assuming the merger is completed November 2, 2026, we will operate as a combined company and the guidance will no longer apply.¹
Financial Results for Quarter Ended September 30, 2026
:
Financial Results for Nine Months Ended September 30, 2026
:
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.²
Columns and rows within financial tables may not foot due to rounding. Percentages and per share data in the financial tables have been calculated using actual, non-rounded figures.
Non-GAAP
Financial Measures
:
Non-GAAP financial measures adjust for non-recurring items and other items representing expenses or income that we believe do not reflect the Company’s ongoing operations or the adjustment of which may help with the comparison to prior periods. The Company believes its non-GAAP financial measures may be useful to investors to understand the Company’s performance. In addition, the Company uses “Adjusted EBITDA” in its annual incentive plan in which all executive officers participate.
Financial statements
Income Statement
Three Months Ended September 30, — Condensed consolidated statements of operations (in millions)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Net revenue | 356 | 314 | 1,016 | 881 |
| Cost of sales | 51 | 83 | 140 | 179 |
| Gross profit | 305 | 230 | 875 | 702 |
| Selling, general and administrative | 119 | 154 | 364 | 445 |
| Research and development | 5 | 33 | 33 | 76 |
| Total operating expenses | 125 | 187 | 398 | 521 |
| Operating income | 180 | 43 | 477 | 181 |
| Interest (income) | -4 | -6 | -9 | -16 |
| Interest expense | 2 | 12 | 10 | 39 |
| Loss on debt extinguishment | 18 | |||
| Income before income taxes | 182 | 37 | 457 | 158 |
| Income tax expense (benefit) | 45 | -5 | 109 | 50 |
| Net income | 137 | 42 | 348 | 108 |
| Earnings per share | ||||
| Basic | 1.16 | 0.34 | 2.89 | 0.87 |
| Diluted | 1.12 | 0.33 | 2.78 | 0.85 |
Income Statement
Three Months Ended September 30, — Selected revenue information (in millions)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| US: | ||||
| SUBLOCADE* | 252 | 203 | 707 | 561 |
| Sublingual & other | 53 | 51 | 160 | 157 |
| OPVEE1 | 8 | 8 | ||
| PERSERIS2 | 2 | 6 | 12 | 19 |
| Total U.S. | 307 | 267 | 880 | 745 |
| Rest of World | 48 | 47 | 136 | 137 |
| Net revenue | 356 | 314 | 1,016 | 881 |
| *Total SUBLOCADE net revenue | 267 | 219 | 753 | 604 |
Income Statement
Three Months Ended September 30, — diluted earnings per share, is included in the table below.
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| GAAP net income | 137 | 42 | 348 | 108 |
| Adjustments in cost of sales1 | 8 | 33 | 13 | 34 |
| Adjustments in operating expenses | 22 | 42 | 67 | 62 |
| Adjustments in interest expense | 4 | |||
| Loss on debt extinguishment | 18 | |||
| Adjustments in tax expenses | -6 | -24 | -19 | 5 |
| Non-GAAP net income | 161 | 93 | 427 | 213 |
| Shares used in computing diluted non-GAAP earnings per share | 122 | 129 | 125 | 127 |
| Non-GAAP diluted earnings per share | 1.32 | 0.72 | 3.41 | 1.68 |
Income Statement
Three Months Ended September 30,
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Net income | 137 | 42 | 348 | 108 |
| Interest (income) | -4 | -6 | -9 | -16 |
| Interest expense | 2 | 12 | 10 | 39 |
| Income tax expense (benefit) | 45 | -5 | 109 | 50 |
| Depreciation and amortization | 1 | 2 | 5 | 8 |
| Stock-based compensation | 8 | 6 | 28 | 21 |
| Corporate initiative transition | 20 | 35 | 45 | 41 |
| Manufacturing transition | 2 | 2 | 6 | 4 |
| Discontinuation of OPVEE sales and marketing | 30 | 30 | ||
| Loss on debt extinguishment | 18 | |||
| Litigation settlement expense | 1 | |||
| Adjusted EBITDA | 211 | 120 | 562 | 286 |
Balance Sheet
September 30, 2026 — Condensed consolidated balance sheets (in millions)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | 305 | 195 |
| Accounts receivable, net of allowances of $3 (2026) and $4 (2025) | 273 | 253 |
| Inventories | 149 | 153 |
| Prepaid expenses | 21 | 34 |
| Current tax receivable | 13 | 2 |
| Other current assets | 40 | 16 |
| Total current assets | 800 | 652 |
| Long-term investments | 27 | 28 |
| Property, plant and equipment, net | 175 | 144 |
| Operating lease right of use assets, net | 12 | 26 |
| Goodwill and other intangible assets, net | 2 | 2 |
| Deferred tax assets | 288 | 323 |
| Other noncurrent assets | 27 | 27 |
| Total assets | 1,332 | 1,201 |
| Current liabilities | ||
| Accrued rebates and product returns | 548 | 582 |
| Accounts payable and accrued expenses | 181 | 250 |
| Accrued litigation settlement expenses, current | 14 | 42 |
| Current portion of long-term debt | 488 | 29 |
| Operating lease liabilities, current | 7 | 10 |
| Income taxes payable | 63 | 2 |
| Total current liabilities | 1,301 | 914 |
| Long-term debt, less current portion | 290 | |
| Accrued litigation settlement expenses, noncurrent | 42 | 52 |
| Operating lease liabilities, noncurrent | 6 | 22 |
| Other noncurrent liabilities | 42 | 21 |
| Total liabilities | 1,392 | 1,300 |
| Stockholders’ deficit | ||
| Common stock, par value $0.001 per share (2026) and $0.50 per share (2025). Issued shares: 118 (2026) and 125 (2025) | 62 | |
| Additional paid-in capital | 163 | 112 |
| Accumulated other comprehensive loss | -26 | -30 |
| Accumulated deficit | -197 | -243 |
| Total stockholders’ deficit | -60 | -98 |
| Total liabilities and stockholders’ deficit | 1,332 | 1,201 |
Cash Flow
Nine Months Ended September 30, — Condensed consolidated statements of cash flows (in millions)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income | 348 | 108 |
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Depreciation and amortization | 5 | 8 |
| Amortization of right-of-use assets | 4 | 7 |
| Stock-based compensation expense | 28 | 21 |
Important Cautionary Note Regarding Forward-Looking Statements
:
This announcement contains certain statements that are forward-looking statements. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements include, among other things, express and implied statements regarding: our 2026 financial guidance including with respect to net revenue, total SUBLOCADE net revenue, non-GAAP operating expenses, and adjusted EBITDA; the expected completion and timing of the closing of our previously announced merger with Supernus, including the payment and timing of the special cash dividend, the expected operation, performance, and prospects of the combined company; potential expense reductions; expected acceleration in SUBLOCADE net revenue and dispense unit growth; expected growth in adjusted EBITDA, cash flow, and our bottom line, and expected acceleration of such growth; expected creation of shareholder value; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,”
“estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,”
“will,” “should,” “would,” “could,” “can,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Prospective investors are cautioned that any such forward-looking... (truncated)arding future results or events which, by their nature, are inherently uncertain and outside of management’s control or ability to predict.
Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including but not limited to: market disruptions or unanticipated delays; lower than expected future sales of our products; greater than expected impacts from competition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; the effect of additional indebtedness incurred to fund the special cash dividend; potential business disruption and diversion of management attention; difficulties integrating the businesses; and potential failure to realize anticipated benefits and synergies. For additional information about some of the risks and important factors that could affect our future results and financial condition, see “Important Cautionary Note Regarding Forward-looking Statements” and “Risk Factors” in Indivior’s Annual Report on Form
10-K filed February 26, 2026, Indivior’s quarterly reports on Form
10-Q for the quarters ended March 31, June 30, and September 30, 2026, the definitive joint proxy statement/prospectus filed September 11, 2026, and our other filings with the U.S. Securities and Exchange Commission.
We have based the forward-looking statements in this release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this release speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether due to new information, or to reflect events or developments that occur after the date the statement was made.
Important Additional Information and Where to Find It
In connection with the proposed merger, Indivior filed a registration statement on Form
S-4 with the SEC, which was declared effective on September 11, 2026 and includes a definitive joint proxy statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BEFORE MAKING ANY VOTING OR INVESTMENT DECISION.
Free copies of these documents and other documents filed by Indivior with the SEC may be obtained at the SEC’s website at www.sec.gov. Copies of Indivior’s filings may also be obtained free of charge on Indivior’s website at www.indivior.com, and copies of Supernus’s filings may be obtained free of charge on Supernus’s website at www.supernus.com.³
No Offer or Solicitation
This announcement is not a solicitation of a proxy, consent or authorization in respect of any securities or in respect of the proposed merger, and it is not an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
For Further Information
:⁴
Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)
Condensed consolidated statements of operations⁵
Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)
Condensed consolidated balance sheets⁶
Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)
Condensed consolidated statements of cash flows⁷
Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)
Selected revenue information
Reconciliation of GAAP to non-GAAP financial information
Non-GAAP diluted earnings per share
Management believes that non-GAAP diluted earnings per share, which excludes the impact of certain non-recurring items and other adjustments, net of applicable tax effects, may provide useful information to shareholders regarding underlying trends in earnings per share. A reconciliation of GAAP net income to non-GAAP net income, as well as the weighted average shares used in computing non-GAAP diluted earnings per share, is included in the table below.⁸
Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense, interest income, income tax expense or benefit, depreciation and amortization, stock-based compensation, and other adjustments reflecting changes in our business that do not represent ongoing operations. Adjusted EBITDA margin is Adjusted EBITDA divided by Total net revenue. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.⁹